论文部分内容阅读
目的:为比较不同样本中DD3 mRNA和hTERTmRNA检测的差异。方法:FQ-PCR方法用于检测32例前列腺癌和31例前列腺增生患者的周血和组织中DD3 mRNA和hTERTmRNA。结果:前列腺癌和前列腺增生患者周血中DD3mRNA阳性率分别为75.00%和16.13%(χ2=21.97,P<0.0001),载量(拷贝对数值)分别为5.58±1.11和4.26±1.51(t=2.16,P=0.030);hTERTmRNA阳性率分别为87.50%和45.16%(χ2=12.70,P=0.000137),载量分别为5.41±1.59和4.27±1.29(t=2.24,P=0.025)。前列腺组织中DD3 mRNA阳性率分别为90.91%和59.09%(χ2=18.43,P<0.0001),载量(拷贝对数值)分别为5.75±1.12和4.43±0.79(t=2.48,P=0.010);hTERT mRNA阳性率分别为95.45%和40.91%(χ2=15.09,P=0.00010),载量分别为5.57±1.48和4.42±1.32(t=1.93,P=0.054)。而DD3 mR-NA阳性率和载量在前列腺癌患者周血和组织中无差异(χ2=2.19,P=0.14;t=0.49,P=0.62),hTERT mRNA也无统计学差异(χ2=0.98,P=0.32;t=0.58,P=0.56)。结论:周血样本与组织样本检测DD3 mRNA和hTERT mRNA诊断前列腺癌灵敏度无差异,周血样本更适用于前列腺癌筛查。
Objective: To compare the differences of DD3 mRNA and hTERT mRNA in different samples. Methods: FQ-PCR was used to detect DD3 mRNA and hTERT mRNA in peripheral blood and tissues from 32 cases of prostate cancer and 31 cases of benign prostatic hyperplasia. Results: The positive rates of DD3 mRNA in peripheral blood of patients with prostate cancer and benign prostatic hyperplasia were 75.00% and 16.13%, respectively (χ2 = 21.97, P <0.0001) and the loading values were 5.58 ± 1.11 and 4.26 ± 1.51 (t = 2.16, P = 0.030). The positive rates of hTERT mRNA were 87.50% and 45.16% respectively (χ2 = 12.70, P = 0.000137). The loading rates were 5.41 ± 1.59 and 4.27 ± 1.29 (t = 2.24, P = 0.025). The positive rates of DD3 mRNA in prostate tissue were 90.91% and 59.09%, respectively (χ2 = 18.43, P <0.0001). The loading values were 5.75 ± 1.12 and 4.43 ± 0.79 respectively (t = 2.48, P = 0.010) The positive rates of hTERT mRNA were 95.45% and 40.91%, respectively (χ2 = 15.09, P = 0.00010). The loading rates were 5.57 ± 1.48 and 4.42 ± 1.32 respectively (t = 1.93, P = 0.054). The positive rate of mR-NA and the load of DD3 in peripheral blood and tissues of patients with prostate cancer were no significant difference (χ2 = 2.19, P = 0.14; t = 0.49, P = 0.62) , P = 0.32; t = 0.58, P = 0.56). Conclusion: The sensitivity of DD3 mRNA and hTERT mRNA in the diagnosis of prostate cancer was no difference between the peripheral blood samples and the tissue samples. The peripheral blood samples were more suitable for the screening of prostate cancer.